Pappa Theodora, Anselmo João, Mamanasiri Sunnee, Dumitrescu Alexandra M, Weiss Roy E, Refetoff Samuel
Departments of Medicine, The University of Chicago, Chicago, Illinois 60637.
Rosalind Franklin University of Medicine and Science, Centegra Health System, McHenry, Illinois 60064.
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3775-3782. doi: 10.1210/jc.2017-01251.
Resistance to thyroid hormone-β (RTH-β) is an autosomal dominant disorder characterized by reduced sensitivity of target tissues to thyroid hormones (THs). Individuals with RTH-β have high TH levels usually due to mutations in the TH receptor-β (THRB) gene. The management of RTH-β during pregnancy is challenging, as wild-type (WT) fetuses born to RTH-β mothers have low birth weight and suppressed postnatal thyroid-stimulating hormone (TSH), due to intrauterine exposure to excess TH.
To determine birth weight and postnatal TSH of WT fetuses carried by mothers with RTH-β whose fT4 levels were maintained below 20% of the upper limit of normal (ULN).
Retrospective chart review.
Academic institution in collaboration with off-site hospitals and private practices.
Thirteen women harboring THRB gene mutations were evaluated during 18 pregnancies.
Prenatal genetic diagnosis by amniocentesis. Women carrying WT fetuses were given the option of treatment with antithyroid medication by their treating physicians with the aim to avoid serum fT4 levels above 20% of the ULN.
No significant difference was found in birth weight corrected for gestational age and in serum TSH levels at birth between WT and RTH-β infants born to RTH-β mothers.
Prenatal diagnosis may play an important role in the management of RTH-β during pregnancy. Aiming for maternal fT4 levels not above 50% of the ULN in RTH-β mothers carrying WT fetuses seems to be a prudent approach that prevents the otherwise expected low birth weight and postnatal TSH suppression.
甲状腺激素β抵抗(RTH-β)是一种常染色体显性疾病,其特征为靶组织对甲状腺激素(THs)的敏感性降低。患有RTH-β的个体通常因甲状腺激素受体β(THRB)基因突变而甲状腺激素水平较高。孕期RTH-β的管理具有挑战性,因为RTH-β母亲所生的野生型(WT)胎儿由于宫内暴露于过量甲状腺激素,出生体重低且出生后促甲状腺激素(TSH)受抑制。
确定RTH-β母亲所怀WT胎儿的出生体重及出生后TSH水平,这些母亲的游离甲状腺素(fT4)水平维持在正常上限(ULN)的20%以下。
回顾性病历审查。
与外地医院及私人诊所合作的学术机构。
13名携带THRB基因突变的女性在18次妊娠期间接受了评估。
通过羊膜穿刺术进行产前基因诊断。携带WT胎儿的女性由其治疗医生选择使用抗甲状腺药物进行治疗,目的是避免血清fT4水平高于ULN的20%。
RTH-β母亲所生的WT婴儿与RTH-β婴儿相比,校正胎龄后的出生体重及出生时的血清TSH水平无显著差异。
产前诊断在孕期RTH-β的管理中可能发挥重要作用。对于携带WT胎儿的RTH-β母亲,将母体fT4水平控制在不高于ULN的50%似乎是一种谨慎的方法,可避免出现预期的低出生体重及出生后TSH受抑制的情况。